| Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia EM Stein, CD DiNardo, DA Pollyea, AT Fathi, GJ Roboz, JK Altman, ... Blood, The Journal of the American Society of Hematology 130 (6), 722-731, 2017 | 1594 | 2017 |
| Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML CD DiNardo, EM Stein, S de Botton, GJ Roboz, JK Altman, AS Mims, ... New England Journal of Medicine 378 (25), 2386-2398, 2018 | 1499 | 2018 |
| Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML AE Perl, G Martinelli, JE Cortes, A Neubauer, E Berman, S Paolini, ... New England Journal of Medicine 381 (18), 1728-1740, 2019 | 1202 | 2019 |
| Targeting FTO suppresses cancer stem cell maintenance and immune evasion R Su, L Dong, Y Li, M Gao, L Han, M Wunderlich, X Deng, H Li, Y Huang, ... Cancer cell 38 (1), 79-96. e11, 2020 | 583 | 2020 |
| Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology MS Tallman, ES Wang, JK Altman, FR Appelbaum, VR Bhatt, D Bixby, ... Journal of the National Comprehensive Cancer Network 17 (6), 721-749, 2019 | 464 | 2019 |
| Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology MR O'Donnell, MS Tallman, CN Abboud, JK Altman, FR Appelbaum, ... Journal of the National Comprehensive Cancer Network 15 (7), 926-957, 2017 | 446 | 2017 |
| Isocitrate dehydrogenase mutations in myeloid malignancies BC Medeiros, AT Fathi, CD DiNardo, DA Pollyea, SM Chan, R Swords Leukemia 31 (2), 272-281, 2017 | 406 | 2017 |
| Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib EM Stein, CD DiNardo, AT Fathi, DA Pollyea, RM Stone, JK Altman, ... Blood, The Journal of the American Society of Hematology 133 (7), 676-687, 2019 | 383 | 2019 |
| Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia GJ Roboz, CD DiNardo, EM Stein, S de Botton, AS Mims, GT Prince, ... Blood, The Journal of the American Society of Hematology 135 (7), 463-471, 2020 | 369 | 2020 |
| Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology PL Greenberg, RM Stone, A Al-Kali, SK Barta, R Bejar, JM Bennett, ... Journal of the National Comprehensive Cancer Network 15 (1), 60-87, 2017 | 344 | 2017 |
| NCCN guidelines insights: acute myeloid leukemia, version 2.2021: featured updates to the NCCN guidelines DA Pollyea, D Bixby, A Perl, VR Bhatt, JK Altman, FR Appelbaum, ... Journal of the National Comprehensive Cancer Network 19 (1), 16-27, 2021 | 287 | 2021 |
| Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia YB Chen, S Li, AA Lane, C Connolly, C Del Rio, B Valles, M Curtis, ... Biology of Blood and Marrow Transplantation 20 (12), 2042-2048, 2014 | 266 | 2014 |
| The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond SA Wander, MJ Levis, AT Fathi Therapeutic advances in hematology 5 (3), 65-77, 2014 | 226 | 2014 |
| Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3‐ITD acute myeloid leukaemia in first complete remission AM Brunner, S Li, AT Fathi, M Wadleigh, VT Ho, K Collier, C Connolly, ... British journal of haematology 175 (3), 496-504, 2016 | 204 | 2016 |
| Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase 1/2 study AT Fathi, CD DiNardo, I Kline, L Kenvin, I Gupta, EC Attar, EM Stein, ... JAMA oncology 4 (8), 1106-1110, 2018 | 200 | 2018 |
| Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study EM Stein, CD DiNardo, AT Fathi, AS Mims, KW Pratz, MR Savona, ... Blood, The Journal of the American Society of Hematology 137 (13), 1792-1803, 2021 | 199 | 2021 |
| Acute lymphoblastic leukemia, version 2.2021, NCCN clinical practice guidelines in oncology PA Brown, B Shah, A Advani, P Aoun, MW Boyer, PW Burke, ... Journal of the National Comprehensive Cancer Network 19 (9), 1079-1109, 2021 | 191 | 2021 |
| Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations A Emadi, SA Jun, T Tsukamoto, AT Fathi, MD Minden, CV Dang Experimental hematology 42 (4), 247-251, 2014 | 189 | 2014 |
| Development and validation of a novel acute myeloid leukemia–composite model to estimate risks of mortality ML Sorror, BE Storer, AT Fathi, AT Gerds, BC Medeiros, P Shami, ... JAMA oncology 3 (12), 1675-1682, 2017 | 175 | 2017 |
| Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML S Choe, H Wang, CD DiNardo, EM Stein, S de Botton, GJ Roboz, ... Blood advances 4 (9), 1894-1905, 2020 | 169 | 2020 |
